Evaluation of efficacy and safety of terazosin in patients with benign prostatic hyperplasia with lower urinary tract symptoms
Not Applicable
- Conditions
- Diseases of The genitoruinary system
- Registration Number
- KCT0005278
- Lead Sponsor
- Yonsei University, Wonju Severance Christian Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Male
- Target Recruitment
- 174
Inclusion Criteria
(1) Male over 40 years old
(2) A person with an IPSS total score of 8 or higher
(3) Those whose maximum urine velocity (Qmax) is less than 10mL/s
(4) Those who have a single void volume of 150 mL or more
(5) A person who consented to participate in this study by handwritten signature
Exclusion Criteria
(1) People who are hypersensitive to Alpha-blocker drugs
(2) People with bladder neck stenosis and urinary tract stenosis
(3) Those with renal dysfunction (creatinine concentration in serum>2.0mg/dL)
(4) People who have a severe liver disorder or have a history
(5) People with severe cardiovascular disease
(6) People with severe hypotension
(7) Other research directors judge that it is inappropriate to participate in this research
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in IPSS(International Prostate Symptom Score) total score
- Secondary Outcome Measures
Name Time Method Change in OABSS(Overactive Bladder Symptom Score) total score;Change in Qmax and Qave;IPSS (International Prostate Symptom Score) Total change rate(~10%, 10-30%, 30%~);Change in IPSS-QoL(International Prostate Symptom Score-Quality of life)